US OptionsDetailed Quotes
PTCT241220P50000
- 6.60
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
6.60Open6.60Pre Close0 Volume6 Open Interest50.00Strike Price0.00Turnover72.83%IV-0.39%PremiumDec 20, 2024Expiry Date6.77Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7399Delta0.0393Gamma5.51Leverage Ratio-0.0487Theta-0.0229Rho-4.07Eff Leverage0.0374Vega
PTC Therapeutics Stock Discussion
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
16
3
$PTC Therapeutics (PTCT.US)$ just dud offering 22.87 a share get out 🔻🔻🔻🔻
PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.
Recent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.
1
PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.
$PTC Therapeutics (PTCT.US)$ 🚀🚀🚀🚀🚀🚀🚀🔥🔥🔥🔥🔥🔥🔥 Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
Columns US Premarket Mover
*Adobe, Canopy Growth, DoorDash, Nikola* US equities were little changed as of 8:51 a.m.
New York time, with Wall Street weighing the latest economic reports ahead of next week’s Federal Reserve decision Here are some of the biggest US movers today: Gainers:
🌟 *Canopy Growth (CGC)* shares jump 20% after the cannabis company ceased funding for BioSteel Sports Nutrition on Thursday
🌟 *Nikola (NKLA)* shares gain 15% putting the electric-vehicle maker on track to extend Thursday...
New York time, with Wall Street weighing the latest economic reports ahead of next week’s Federal Reserve decision Here are some of the biggest US movers today: Gainers:
🌟 *Canopy Growth (CGC)* shares jump 20% after the cannabis company ceased funding for BioSteel Sports Nutrition on Thursday
🌟 *Nikola (NKLA)* shares gain 15% putting the electric-vehicle maker on track to extend Thursday...
6
$Advanced Health Intelligence (AHI.US)$ $AST SpaceMobile (ASTS.US)$ $Boeing (BA.US)$ $Four Corners Property Trust Inc (FCPT.US)$ $FingerMotion (FNGR.US)$ $Locafy (LCFY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Realty Income (O.US)$ $Panbela Therapeutics (PBLA.US)$ $ShiftPixy (PIXY.US)$ $PTC Therapeutics (PTCT.US)$ $RLI Corp (RLI.US)$ $Transcode Therapeutics (RNAZ.US)$ $Steel Connect (STCN.US)$
2
1
$Applied Optoelectronics (AAOI.US)$ $Ault Disruptive Technologies Corporation (ADRT.US)$ $AlloVir (ALVR.US)$ $BranchOut Food (BOF.US)$ $Chemomab Therapeutics (CMMB.US)$ $Cognizant (CTSH.US)$ $Greenpro Capital (GRNQ.US)$ $IDEX Corp (IEX.US)$ $Eightco Holdings (OCTO.US)$ $ShiftPixy (PIXY.US)$ $Root Inc (ROOT.US)$ $PTC Therapeutics (PTCT.US)$ $Summit Therapeutics (SMMT.US)$ $ZoomInfo (ZI.US)$
4
No comment yet
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long